Atlas Trials

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Clinical trial NCT06767813 · RECRUITING

Trial details

NCT number
NCT06767813
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Neoplasms
Start date
2024-03-19
Primary completion
2026-11-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.